Meeting
2024 ASCO Annual Meeting
First-line treatment preferences for advanced melanoma among oncologists and patients in the US: A discrete choice experiment.
Authors
Michael A. Postow
Memorial Sloan Kettering Cancer Center, New York, NY
Michael A. Postow , Gabriela Burgos , Marc DeCongelio , Jennell Palaia , Flavia Ejzykowicz , Divya Patel , Lisa Rosenblatt , Kushal Modi , Zander Pittman , Ryan Honomichl , Neelanzana Paudel , Cody Barnett , Jennifer L. Hay
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 9539)
DOI
10.1200/JCO.2024.42.16_suppl.9539
Abstract #
9539
Poster Bd #
323
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).
First Author: Dirk Schadendorf
Poster
2022 ASCO Annual Meeting
Safety and efficacy results from the expansion phase of the first-in-human study evaluating TGFβ inhibitor SAR439459 alone and combined with cemiplimab in adults with advanced solid tumors.
First Author: Debbie Robbrecht
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I.
First Author: Georgina V. Long
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy and toxicities of immune checkpoint inhibitors (ICIs) in advanced melanoma: A single institution experience.
First Author: Karim Welaya